CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PAL...
Phase 2
Rochester, Minnesota, United States and 7 other locations
dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are:* W ...
Phase 1
Rochester, Minnesota, United States and 3 other locations
triple negative (TN) or hormone receptor positive/HER2-negative breast cancer.The names of the study interventions involved in this...
Phase 2
Rochester, Minnesota, United States and 9 other locations
This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which...
Phase 2
Rochester, Minnesota, United States and 9 other locations
Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies avail...
Phase 3
Rochester, Minnesota, United States and 78 other locations
in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negativ ...
Phase 1
Rochester, Minnesota, United States and 1 other location
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Rochester, Minnesota, United States and 107 other locations
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and whi ...
Phase 2
Rochester, Minnesota, United States and 8 other locations
growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 85 other locations
The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers ...
Phase 1, Phase 2
Rochester, Minnesota, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal